126 related articles for article (PubMed ID: 19903786)
1. PIK3CA mutations predict local recurrences in rectal cancer patients.
He Y; Van't Veer LJ; Mikolajewska-Hanclich I; van Velthuysen ML; Zeestraten EC; Nagtegaal ID; van de Velde CJ; Marijnen CA
Clin Cancer Res; 2009 Nov; 15(22):6956-62. PubMed ID: 19903786
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
3. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors.
de Bruin EC; van de Velde CJ; van de Pas S; Nagtegaal ID; van Krieken JH; Gosens MJ; Peltenburg LT; Medema JP; Marijnen CA
Clin Cancer Res; 2006 Nov; 12(21):6432-6. PubMed ID: 17085656
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
6. Caspase-3 activity predicts local recurrence in rectal cancer.
de Heer P; de Bruin EC; Klein-Kranenbarg E; Aalbers RI; Marijnen CA; Putter H; de Bont HJ; Nagelkerke JF; van Krieken JH; Verspaget HW; van de Velde CJ; Kuppen PJ;
Clin Cancer Res; 2007 Oct; 13(19):5810-5. PubMed ID: 17908973
[TBL] [Abstract][Full Text] [Related]
7. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.
Kalady MF; Sanchez JA; Manilich E; Hammel J; Casey G; Church JM
Dis Colon Rectum; 2009 Jun; 52(6):1039-45. PubMed ID: 19581844
[TBL] [Abstract][Full Text] [Related]
8. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
[TBL] [Abstract][Full Text] [Related]
9. Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences?
He Y; Van't Veer LJ; Lopez-Yurda M; van de Velde CJ; Marijnen CA
Clin Cancer Res; 2010 Dec; 16(24):6179. PubMed ID: 21169263
[No Abstract] [Full Text] [Related]
10. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
11. Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer.
de Maat MF; van de Velde CJ; Benard A; Putter H; Morreau H; van Krieken JH; Meershoek Klein-Kranenbarg E; de Graaf EJ; Tollenaar RA; Hoon DS
Clin Cancer Res; 2010 May; 16(10):2811-8. PubMed ID: 20460484
[TBL] [Abstract][Full Text] [Related]
12. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
13. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
14. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
15. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.
Peng J; Lin J; Qiu M; Zhao Y; Deng Y; Shao J; Ding P; Zhang H; Wan D; Lu Z; Pan Z
Tumour Biol; 2017 Jul; 39(7):1010428317709638. PubMed ID: 28671043
[TBL] [Abstract][Full Text] [Related]
16. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.
Abdul-Jalil KI; Sheehan KM; Toomey S; Schmid J; Prehn J; O'Grady A; Cummins R; O'Neill B; McNamara DA; Deasy J; Breathnach O; Grogan L; Rogers A; Doherty G; Winter D; Ryan J; El-Masry S; Gibbons D; Sheahan K; Gillen P; Kay EW; Hennessy BT
Ann Surg Oncol; 2014 Aug; 21(8):2642-9. PubMed ID: 24700299
[TBL] [Abstract][Full Text] [Related]
17. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
[TBL] [Abstract][Full Text] [Related]
18. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
19. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
[TBL] [Abstract][Full Text] [Related]
20. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]